TOPLINE:During the 2022-2023 influenza season, an adjuvanted quadrivalent influenza vaccine (aQIV) and high-dose (HD) QIV showed comparable effectiveness at preventing test-confirmed influenza among US adults aged 65 years or older across all hospital settings.METHODOLOGY:Researchers conducted a retrospective study using the test-negative design to evaluate the effectiveness of the aQIV vs HD-QIV in preventing laboratory-confirmed influenza […]
